Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Charles River Laboratories Intl (CRL)
NYSE:CRL
Holding CRL?
Track your performance easily
CRL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$176.48 - $275.00
Previous Close$185.77
Volume1.14M
Average Volume (3M)697.30K
Market Cap
$9.31B
Enterprise Value$11.91B
Total Cash (Recent Filing)$210.17M
Total Debt (Recent Filing)$2.76B
Price to Earnings (P/E)22.9
Beta1.68
Next Earnings
Feb 12, 2025EPS Estimate
$2.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.10
Shares Outstanding51,136,178
10 Day Avg. Volume817,108
30 Day Avg. Volume697,299
Standard Deviation0.11
R-Squared0.44
Alpha-0.00586
Financial Highlights & Ratios
Price to Book (P/B)2.55
Price to Sales (P/S)2.28
Price to Cash Flow (P/CF)12.00
P/FCF Ratio15.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.93
Enterprise Value/Gross Profit7.93
Enterprise Value/Ebitda12.40
Forecast
1Y Price Target
$206.40Price Target Upside11.11% Upside
Rating ConsensusHold
Number of Analyst Covering12
Charles River Labs News
PremiumCompany Announcements
Charles River Laboratories Reports 2024 Q3 Financial Results
Bulls Say, Bears Say
Bulls Say
Cost ManagementRestructuring initiatives are set to realize $200M in cumulative annualized cost savings by 2026.
Earnings PerformanceCRL posted a record quarter in free cash flow, with capital expenditure now showing a pause or reduction compared to previous years.
Market PositionOver the longer-term, CRL is seen as a high-quality market leader in preclinical drug development.
Bears Say
Financial PerformanceRevenue and earnings in the third quarter showed declines in several segments, with revenue down 2.7%, operating income down 4.9%, and earnings per share down 4.7%.
Market ConditionsMore than 80% of CRL is in markets that don’t currently bring growth, where certain costs are increasing, and pricing is, or may soon be, weakening.
Research And Development SpendingWorsening pharma R&D spending is likely to weigh on preclinical demand.
---
Ownership Overview
0.94% Insiders
27.12% Mutual Funds
33.35% Other Institutional Investors
13.83% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRL FAQ
What was Charles River Laboratories Intl’s price range in the past 12 months?
Charles River Laboratories Intl lowest stock price was $176.48 and its highest was $275.00 in the past 12 months.
What is Charles River Laboratories Intl’s market cap?
Currently, no data Available
When is Charles River Laboratories Intl’s upcoming earnings report date?
Charles River Laboratories Intl’s upcoming earnings report date is Feb 12, 2025 which is in 53 days.
How were Charles River Laboratories Intl’s earnings last quarter?
Charles River Laboratories Intl released its earnings results on Nov 06, 2024. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.423 by $0.167.
Is Charles River Laboratories Intl overvalued?
According to Wall Street analysts Charles River Laboratories Intl’s price is currently Undervalued.
Does Charles River Laboratories Intl pay dividends?
Charles River Laboratories Intl does not currently pay dividends.
What is Charles River Laboratories Intl’s EPS estimate?
Charles River Laboratories Intl’s EPS estimate is $2.54.
How many shares outstanding does Charles River Laboratories Intl have?
Charles River Laboratories Intl has 51,136,177 shares outstanding.
What happened to Charles River Laboratories Intl’s price movement after its last earnings report?
Charles River Laboratories Intl reported an EPS of $2.59 in its last earnings report, beating expectations of $2.423. Following the earnings report the stock price went up 13.526%.
Which hedge fund is a major shareholder of Charles River Laboratories Intl?
Among the largest hedge funds holding Charles River Laboratories Intl’s share is Eminence Capital LLC. It holds Charles River Laboratories Intl’s shares valued at 198M.
---
Charles River Labs Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$206.40 (11.11% Upside)
$206.40 (11.11% Upside)
Blogger Sentiment
Bullish
CRL Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.79%
12-Months-Change
Fundamentals
Return on Equity
11.81%
Trailing 12-Months
Asset Growth
5.22%
Trailing 12-Months
Company Description
Charles River Laboratories Intl
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support. The Research Models & Services segment comprises of the production and sale of research models, and also offers services designed to support its client's use of research models in screening non-clinical drug candidates. The Discovery & Safety Assessment segment offers discovery and safety assessment services, both regulated and non-regulated, in which it include both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Manufacturing Support segment provides endotoxin and microbial detection, avian vaccine and biologics testing solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.
---
CRL Company Deck
---
CRL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call indicates a challenging environment with some positive signals of stabilization. Record free cash flow and strong performance in the Manufacturing segment are notable achievements. However, the decline in organic revenue, particularly in the DSA segment, and challenges with global biopharmaceutical clients weigh on the sentiment. The company's efforts in cost savings and stock repurchases are steps in the right direction, but the current demand environment remains uncertain.Read More>---
CRL Revenue Breakdown
63.34% DSA
19.19% RMS
17.47% Manufacturing
---
CRL Stock 12 Month Forecast
Average Price Target
$206.40
▲(11.11% Upside)
Technical Analysis
Best Analysts Covering CRL
1 Year
1 Year Success Rate
7/10 ratings generated profit
1 Year Average Return
+17.09%
reiterated a sell rating last month
Copying Patrick B Donnelly's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +17.09% per trade.
---